Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Short Interest Update

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) was the target of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 21,100 shares, a decrease of 60.9% from the February 28th total of 53,900 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 28,500 shares, the short-interest ratio is presently 0.7 days.

Inhibitor Therapeutics Price Performance

Shares of INTI opened at $0.06 on Thursday. The firm has a market capitalization of $9.51 million, a PE ratio of -5.52 and a beta of -0.55. The company has a 50-day simple moving average of $0.06 and a two-hundred day simple moving average of $0.07. Inhibitor Therapeutics has a one year low of $0.04 and a one year high of $0.14.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.